ClinicalTrials.gg
CompletedNCT00761306Updated Jan 29, 2014Results posted

Open-label Safety Extension Study of 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults

A Phase 2 interventional study of Vortioxetine (Lu AA21004) in Major Depressive Disorder, sponsored by H. Lundbeck A/S. Completed. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-01-29.

Sponsored by H. Lundbeck A/S · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
74
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 54 studies testing vortioxetine in Depressive Disorder, Major — 1 open to participants now, 1 under way, 1 of them phase 3. Vortioxetine · Depressive Disorder, Major.

Enrollment
45th of 54
74 · median 413
Started
2007
with 1 other
Phase 2
6 of 54
none open now
Registered
8th of 54
by date
Lead sponsor
24 of 54
H. Lundbeck A/S

Among the 54 studies testing vortioxetine in Depressive Disorder, Major, this one is the 45th largest by enrollment, is one of 2 that started in 2007, is one of 6 in phase 2, and was the 8th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

1 of the 54 studies testing vortioxetine in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About vortioxetine

Vortioxetine: first FDA approval 2013 (TRINTELLIX), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 413 Depressive Disorder, Major studies recruiting now, 93 (23%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing vortioxetine in Depressive Disorder, Major, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate long-term safety and tolerability of Vortioxetine over a period of 52 weeks in patients with Major Depressive Disorder (MDD) having completed 6-week acute treatment in study NCT00839423 / 11492A.

03

Conditions studied

  • Major Depressive Disorder

Keywords

  • Major Depressive Disorder
  • Long-term
  • Safety
  • Open-label
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who completed 6-week short-term treatment study for Major Depressive Episode (MDE), NCT00839423 / 11492A, followed by a 2-week taper period

Exclusion criteria

Exclusion Criteria:

  • Any current psychiatric disorder other than MDD as defined in the , 4th Edition, Text Revision (DSM-IV TR)
  • Female patients of who are not using effective
  • Use of any psychoactive medication

Other protocol-defined inclusion and exclusion criteria may apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
74 participants (actual)

Study arms

  • Experimental
    Vortioxetine

    Drug: Vortioxetine (Lu AA21004)

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Patients With Adverse Events (AEs)

    Time frame: Up to 52 weeks and a 4-week safety follow-up period

  2. Percentage of Patients Who Withdrew Due to Intolerance to Treatment

    Time frame: Baseline to Week 52

Secondary outcomes

  1. Change From Baseline in MADRS Total Score After 52 Weeks of Treatment

    The Montgomery Åsberg Depression Rating Scale (MADRS) is a depression rating scale consisting of 10 items, each rated 0 (no symptom) to 6 (severe symptom). The 10 items represent the core symptoms of depressive illness. The rating should be based on a clinical interview with the patient, moving from broadly phrased questions about symptoms to more detailed ones, which allow a precise rating of severity, covering the last 7 days. Total score from 0 to 60. The higher the score, the more severe.

    Time frame: Baseline and Week 52

  2. Change From Baseline in HAM-D-24 Total Score After 52 Weeks of Treatment

    The Hamilton Depression Scale - 24 Items (HAM-D-24) measures depression severity. Items are rated on a scale from 0 (symptoms not present) to a maximum of 2 to 4 (symptom extremely severe) for a total score range of 0 to 76. The higher the score, the more severe.

    Time frame: Baseline and Week 52

  3. Proportion of Responders at Week 52 (Response Defined as a >=50% Decrease in MADRS Total Score)

    Time frame: Week 52

  4. Proportion of Remitters at Week 52 (Remission Defined as a MADRS Total Score <=10)

    Time frame: Week 52

07

Results

Posted Dec 17, 2013

Participant flow

Patients eligible to participate in present study, NCT00761306 / 11492C, were outpatients, who had completed lead-in study NCT00839423 / 11492A immediately prior to inclusion into present study.

Participant flow — Overall Study
MilestoneVortioxetine 5 or 10 mg/Day
Started74
Completed54
Not completed20
Withdrew: Adverse event5
Withdrew: Lack of efficacy4
Withdrew: Protocol violation2
Withdrew: Withdrawal of consent3
Withdrew: Lost to follow-up1
Withdrew: Administrative or other reasons5

Outcome measures

PrimaryNumber of Patients With Adverse Events (AEs)
Time frame:
Up to 52 weeks and a 4-week safety follow-up period
Reported as:
Number · participants
Number of Patients With Adverse Events (AEs)
participantsVortioxetine 5 or 10 mg/Day
Patients With AEs64
Patients With SAEs1
Patients With AEs Leading to Withdrawal5
Patients With Baseline Events16
PrimaryPercentage of Patients Who Withdrew Due to Intolerance to Treatment
Time frame:
Baseline to Week 52
Reported as:
Number · percentage of patients
Percentage of Patients Who Withdrew Due to Intolerance to Treatment
percentage of patientsVortioxetine 5 or 10 mg/Day
Percentage of Patients Who Withdrew Due to Intolerance to Treatment6.8
SecondaryChange From Baseline in MADRS Total Score After 52 Weeks of Treatment

The Montgomery Åsberg Depression Rating Scale (MADRS) is a depression rating scale consisting of 10 items, each rated 0 (no symptom) to 6 (severe symptom). The 10 items represent the core symptoms of depressive illness. The rating should be based on a clinical interview with the patient, moving from broadly phrased questions about symptoms to more detailed ones, which allow a precise rating of severity, covering the last 7 days. Total score from 0 to 60. The higher the score, the more severe.

Time frame:
Baseline and Week 52
Reported as:
Mean · units on a scale
Change From Baseline in MADRS Total Score After 52 Weeks of Treatment
units on a scaleVortioxetine 5 or 10 mg/Day
Change From Baseline in MADRS Total Score After 52 Weeks of Treatment-4.33 ± 9.24
SecondaryChange From Baseline in HAM-D-24 Total Score After 52 Weeks of Treatment

The Hamilton Depression Scale - 24 Items (HAM-D-24) measures depression severity. Items are rated on a scale from 0 (symptoms not present) to a maximum of 2 to 4 (symptom extremely severe) for a total score range of 0 to 76. The higher the score, the more severe.

Time frame:
Baseline and Week 52
Reported as:
Mean · units on a scale
Change From Baseline in HAM-D-24 Total Score After 52 Weeks of Treatment
units on a scaleVortioxetine 5 or 10 mg/Day
Change From Baseline in HAM-D-24 Total Score After 52 Weeks of Treatment-3.46 ± 8.72
SecondaryProportion of Responders at Week 52 (Response Defined as a >=50% Decrease in MADRS Total Score)
Time frame:
Week 52
Reported as:
Number · percentage of patients
Proportion of Responders at Week 52 (Response Defined as a >=50% Decrease in MADRS Total Score)
percentage of patientsVortioxetine 5 or 10 mg/Day
Proportion of Responders at Week 52 (Response Defined as a >=50% Decrease in MADRS Total Score)92.7
SecondaryProportion of Remitters at Week 52 (Remission Defined as a MADRS Total Score <=10)
Time frame:
Week 52
Reported as:
Number · percentage of patients
Proportion of Remitters at Week 52 (Remission Defined as a MADRS Total Score <=10)
percentage of patientsVortioxetine 5 or 10 mg/Day
Proportion of Remitters at Week 52 (Remission Defined as a MADRS Total Score <=10)81.8

Adverse events

Collected over Serious Adverse Events: 52-week open label period and 4-week safety follow-up period Other Adverse Events: 52-week open label period. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vortioxetine 5 or 10 mg/Day—1/74 (1.4%)53/74 (71.6%)
Most frequent serious events
Most frequent serious events
EventVortioxetine 5 or 10 mg/Day
ThyroiditisEndocrine disorders1/74
Most frequent other events
Most frequent other events
EventVortioxetine 5 or 10 mg/Day
NauseaGastrointestinal disorders20/74
NasopharyngitisInfections and infestations17/74
Weight increasedInvestigations14/74
HeadacheNervous system disorders10/74
DiarrhoeaGastrointestinal disorders6/74
FatigueGeneral disorders5/74
DizzinessNervous system disorders5/74
InsomniaPsychiatric disorders5/74
GastroenteritisInfections and infestations4/74

Baseline characteristics

Age and Sex: all-patients-treated set (APTS) - all patients who took at least one dose of Vortioxetine in Study NCT00761306 / 11492C; MADRS and HAM-D-24: full-analysis set (FAS) = 74 - all patients in the APTS who had at least one valid Baseline and one valid post-Baseline assessment of the MADRS total score in Study NCT00761306 / 11492C.

Age, Continuous
Age, Continuous(years)Vortioxetine 5 or 10 mg/Day
Mean44.5 ± 11.5
Sex: Female, Male
Sex: Female, Male(Participants)Vortioxetine 5 or 10 mg/Day
Female45
Male29
MADRS
MADRS(units on a scale)Vortioxetine 5 or 10 mg/Day
Mean10.7 ± 8.4
HAM-D-24
HAM-D-24(units on a scale)Vortioxetine 5 or 10 mg/Day
Mean10.2 ± 7.8
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2007, a primary completion of Sep 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2013, 5 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2008
First posted
Sep 29, 2008
Start
Jun 2007
Primary completionActual
Sep 2008
CompletionActual
Oct 2008
Results first posted
Dec 17, 2013
Last update
Jan 29, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 29, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00761306
Lead sponsor
H. Lundbeck A/S
Responsible party
Sponsor
First posted
Sep 29, 2008
Start date
Jun 2007
Primary completion
Sep 2008
Completion
Oct 2008
Results posted
Dec 17, 2013
Last update
Jan 29, 2014

Study contacts

Email contact via H. Lundbeck A/S
study director · LundbeckClinicalTrials@lundbeck.com

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vortioxetine

Start the discussion